Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Coronavirus Update: What patients and families need to know

KYMRIAH Treatment

Children's National offers KYMRIAH® (tisagenlecleucel), which is a prescription cancer treatment for our pediatric patients with relapsed or refractory B-cell ALL. If previous treatment methods were unable to keep your child's cancer in remission, KYMRIAH may help your child beat cancer.

KYMRIAH is a cutting-edge immunocellular therapy that uses your child's own immune system to treat their cancer. It happens in three stages:

  • Collection. First, your child's doctor will take some of your child's blood to collect their T cells. Then, they are frozen and sent to be reprogrammed into KYMRIAH CAR-T cells.
  • Reprogramming. Next, your child's T cells are reprogrammed into KYMRIAH CAR-T cells. The CAR in CAR-T stands for chimeric antigen receptor. This CD19-detecting receptor gives your child's T cells a new way to target their B cells.
  • Infusion. Once your child's KYMRIAH CAR-T cells are returned to his or her body, they are ready to begin detecting and destroying their cancer.

At Children's National, our dedicated team of cancer experts can discuss your child's treatment history and overall health to see if they are a candidate for KYMRIAH therapy. Learn more.

Contact Information

For questions or more information about KYMRIAH®, please contact Dennise Lim or call 202-476-1735.